Puma Biotechnology (PBYI)
(Delayed Data from NSDQ)
$2.54 USD
+0.10 (4.10%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.54 USD
+0.10 (4.10%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Puma Biotech (PBYI) Up 7.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Moving Average Crossover Alert: Puma Biotechnology
by Zacks Equity Research
Puma Biotechnology, Inc. (PBYI) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Puma Biotechnology, Inc. (PBYI) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Puma Biotechnology, Inc. (PBYI).
New Strong Buy Stocks for May 13th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Puma's (PBYI) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Puma Biotech's (PBYI) loss and revenues better estimates in the first quarter of 2020.
Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 45.57% and 16.97%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Puma Biotech (PBYI) Q1 Earnings Expected to Decline
by Zacks Equity Research
Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Puma Biotech (PBYI) Down 44% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Puma Biotech's (PBYI) Nerlynx Aids Growth Despite Competition
by Zacks Equity Research
Puma Biotech (PBYI) focuses on improving sales of its only marketed drug Nerlynx, which is approved for treating breast cancer. High dependence on Nerlynx for growth remains a woe.
Puma (PBYI) Stock Down Despite Q4 Earnings & Sales Beat
by Zacks Equity Research
Puma Biotech (PBYI) incurs narrower loss in Q4 and tops sales estimates. Sales of Nerlynx decline year over year. Stock drops 10%.
Puma Biotech's (PBYI) Breast Cancer Drug Nerlynx Aids Growth
by Zacks Equity Research
Puma Biotech (PBYI) focuses on improving sales of its only marketed drug Nerlynx, which is approved for treating breast cancer. The drug's label expansion programs also look promising.
Implied Volatility Surging for Puma Biotechnology (PBYI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.
Blueprint Medicines Initiates Dosing in Liver Cancer Study
by Zacks Equity Research
Blueprint Medicines (BPMC) and partner CStone begin dosing in the phase Ib/II study on fisogatinib and CS1001 combo for treating patients with locally advanced/metastatic hepatocellular carcinoma.
Why Is Puma Biotech (PBYI) Down 1% Since Last Earnings Report?
by Zacks Equity Research
Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Puma Biotech Expands Pierre Fabre License to Add Countries
by Zacks Equity Research
Puma Biotech (PBYI) stretches its license deal with Pierre Fabre, granting the latter commercial rights to Nerlynx in new countries across Europe and parts of Africa. Stock rallies.
Implied Volatility Surging for Puma Biotechnology (PBYI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.
Puma (PBYI) Q3 Earnings Beat, Nerlynx Sales Weak, Stock Down
by Zacks Equity Research
Puma Biotech (PBYI) incurs narrower loss in Q3. Sales of Nerlynx decline sequentially. Stock drops 18%.
Puma Biotech (PBYI) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 42.11% and -7.43%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Puma Biotech (PBYI) Q3 Earnings Expected to Decline
by Zacks Equity Research
Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Puma Biotech Gets FDA Nod of Labeling Supplement for Nerlynx
by Zacks Equity Research
The FDA approves the label update of Puma Biotech's (PBYI) breast cancer drug Nerlynx in order to add data from the CONTROL study. Stock gains.
Do Options Traders Know Something About Puma Biotech (PBYI) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Puma Biotech (PBYI) stock based on the movements in the options market lately.
Roche's New Perjeta Combo Meets Goal in Breast Cancer Study
by Zacks Equity Research
Roche's (RHHBY) new fixed-dose combination of Perjeta and Herceptin meets the primary endpoint in the phase III study for treating patients with HER2-positive early breast cancer.
Puma Biotech's sNDA for Nerlynx Combo Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts for review Puma Biotech's (PBYI) sNDA that seeks an approval for Nerlynx in combination with Roche's Xeloda for treating third-line breast cancer.
Why Is Puma Biotech (PBYI) Up 16.8% Since Last Earnings Report?
by Zacks Equity Research
Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Puma (PBYI) Q2 Earnings Miss, Nerlynx Sales Rise, Stock Up
by Zacks Equity Research
Puma Biotech (PBYI) incurs wider loss in Q2. Sales of Nerlynx improve from first-quarter levels. Stock rises 23%.